Joseph Allen Image

Joseph Allen

President

Joseph Allen & Associates

Joe Allen served on the U.S. Senate Judiciary Committee for Senator Birch Bayh (D-IN) securing passage of the Bayh-Dole Act which fostered R&D partnerships between universities and U.S. industry.  The Economist Technology Quarterly called this law “possibly the most inspired piece of legislation to be enacted in America over the past half century.” On leaving the Senate staff, Joe was Executive Director of Intellectual Property Owners, Inc. (IPO) where he worked to create the Court of Appeals for the Federal Circuit before going to the U.S. Department of Commerce where he became the Director of the Office of Technology Commercialization. He was instrumental in the passage of major laws allowing U.S. industry to perform joint R&D with federal laboratories. Allen’s office oversaw Executive branch implementation of the Bayh-Dole and Federal Technology Transfer Acts and related presidential policy directives. He helped negotiate intellectual property rights provisions for major international science and technology agreements.

Joe then became President of the National Technology Transfer Center established by Congress to promote industry/federal laboratory R&D partnerships. He is now the Executive Director of the Bayh-Dole Coalition, a non-profit organization composed of universities, companies, venture capitalists, entrepreneurs and others who are committed to celebrating and protecting the landmark law. Joe writes a monthly column for IP Watchdog on Bayh-Dole related issues.

Recent Articles by Joseph Allen

Making Licensing Harder Doesn’t Boost U.S. Manufacturing

While it’s appropriate to lament the lack of bipartisan cooperation in Washington, just because something’s bipartisan doesn’t mean it’s a good idea. Exhibit A could be Senator Tammy Baldwin (D-WI) and Senator J.D. Vance’s (R-OH) “Invent It Here, Make It Here” bill. Despite the name and its good intentions, it condemns promising federally funded inventions to waste away without doing a thing to build our domestic manufacturing base. It’s scheduled to be considered this Thursday in the Senate Commerce, Science and Transportation Committee.

March-In Drive Loses a Wheel: Generics Industry Says No to Biden Framework

In what has to be the unkindest cut of all, those expected to benefit from the proposed misuse of march-in rights so the government can impose drug price controls say they don’t support it either. The proponents promoting this hot house theory have seen it denounced by those who created the Bayh-Dole Act as being unauthorized under their law and seen evidence they can’t refute that it would have little impact on drug prices but would devastate small business entrepreneurs in all fields of federally supported research and development. And now they’ve lost the generic drug industry.

Past Events with Joseph Allen

IPWatchdog LIVE 2022

September 11-13, 2022